Phase I study of pyrazofurin in refractory acute myelogenous leukemia.

Pyrazofurin was administered to 17 patients with refractory acute myelogenous leukemia in 5-day courses every 2-3 weeks. Doses ranged from 30 to 60 mg/m2/day. Severe stomatitis and dermatitis occurred at doses effective in reducing the leukocyte count (45 mg/m2). Reduction of the dose to 30 mg/m2 resulted in less toxicity and less chemotherapeutic effect. These results indicate that at tolerable doses given as described, pyrazofurin had little antileukemic activity in acute myeologenous leukemia.